MedTrace Logo

Safety, Tolerability and Efficacy of Weekly TV-1106 in Adults With Growth Hormone Deficiency

NCT01811576 · Status: COMPLETED · Phase: PHASE2 · Type: INTERVENTIONAL · Enrollment: 52

Last updated 2021-12-10

No results posted yet for this study

Summary

The primary objective of this study is to evaluate the clinical effect of TV-1106.

Conditions

  • Growth Hormone Deficiency

Interventions

DRUG

TV-1106

DRUG

Recombinant human growth hormone

Subcutaneous once daily

Sponsors & Collaborators

  • Teva Branded Pharmaceutical Products R&D, Inc.

    lead INDUSTRY

Study Design

Allocation
RANDOMIZED
Purpose
TREATMENT
Masking
NONE
Model
PARALLEL

Eligibility

Min Age
23 Years
Max Age
65 Years
Sex
ALL
Healthy Volunteers
No

Timeline & Regulatory

Start
2013-03-31
Primary Completion
2013-08-05
Completion
2013-08-05

Countries

  • United States
  • Czechia
  • Germany
  • Greece
  • Hungary
  • Israel
  • Serbia
  • Slovakia
  • Slovenia

Study Locations

More Related Trials

Read the full study record

This page highlights key information. For complete eligibility criteria, study locations, investigator contacts, and the full protocol, visit the original record on ClinicalTrials.gov.

View NCT01811576 on ClinicalTrials.gov